We are committed to providing access to affordable and innovative medicines, driven by our purpose of ‘Good Health Can’t Wait’.
Our products and services are spread across our core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products around the world. We work towards meeting unmet patients needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. We are investing in businesses of the future including drug discovery, clinically-differentiated assets and digital healthcare.
We started in 1984 with a modest investment and a bold vision.
Today, with research and development centres, manufacturing facilities and commercial
presence across the globe, we serve over half a billion patients worldwide. We aspire to
triple our reach and touch over 1.5 billion patients by 2030.